Ag. Wong et al., EFFECTS OF LONG-ACTING AND SHORT-ACTING BETA-AGONISTS ON METHACHOLINEDOSE-RESPONSE CURVES IN ASTHMATICS, The European respiratory journal, 10(2), 1997, pp. 330-336
Regular use of short-acting beta-agonists may decrease control of asth
ma and increase airway responsiveness to bronchoconstrictor stimuli. T
he aim of this study was to determine the effects of regular treatment
with the long-acting beta-agonist, salmeterol, on the methacholine do
se-response curve (DRC) in mild-to-moderate asthmatics. Changes in met
hacholine airway responsiveness were measured in 14 stable adult asthm
atics, randomized in a double-blind, three-way cross-over design to re
ceive salmeterol 50 mu g, salbutamol 200 mu g or placebo, each twice d
aily for 4 days. Two baseline methacholine DRC, mere performed, one wi
thout premedication and one following a single dose of 200 mu g salbut
amol. Following 4 days of regular treatment, methacholine DRC to plate
au were carried out commencing 15 min after the final dose of trial me
dication. There were no significant differences in mean baseline force
d expiratory volume in one second (FEV(1)) between treatments. Four da
ys treatment with salmeterol and salbutamol shifted the DRC to the rig
ht, but salmeterol provided less protection than salbutamol. The point
of inflection of the curve from baseline moved 1.9 and 3.2 doubling d
oses, respectively, compared to placebo (p less than or equal to 0.001
), and the provocative concentration of methacholine required to produ
ce a 20% fall in FEV(1) (PC20) increased 1.6 and 3.1 doubling doses, r
espectively (p less than or equal to 0.001). The slope of the DRC was
increased slightly by both beta-agonists compared to placebo (log slop
e 3.11, 3.06 and 2.77 for salmeterol, salbutamol and placebo, respecti
vely). This effect of regular salmeterol on slope was more marked in s
ubjects with lower baseline FEV(1). Maximal response plateaus did not
differ between the three treatments.These results suggest that regular
use either of short- or long-acting beta-agonists could increase the
risk, of a more precipitous asthma episode associated with ''breakthro
ugh'' bronchoconstrictor responses, particularly in those with more se
vere initial airflow obstruction, if subjects are exposed to a suffici
ently potent stimulus.